# DESCRIPTION

## TECHNICAL FIELD

- introduce JAK1 modulators for CLE and LP treatment

## BACKGROUND

- describe CLE and LP pathologies
- limitations of current treatments

## SUMMARY

- summarize JAK1 inhibitor-based treatment method

## DETAILED DESCRIPTION

- define cutaneous lupus erythematosus
- describe subtypes of cutaneous lupus erythematosus
- motivate role of type I IFNs in lupus erythematosus
- discuss therapeutic strategies for lupus erythematosus
- introduce JAK family and inhibitors
- discuss JAK inhibitors in CLE and associated skin disorders
- describe limitations of JAK inhibitors and CLASI scoring system
- provide JAK1 inhibitors and their selectivity
- describe specific JAK1 inhibitors and their synthesis
- define JAK1 inhibitors
- describe synthesis and preparation
- define compounds of Formula II
- define compounds of Formula III
- describe method of treating cutaneous lupus erythematosus
- describe method of treating cutaneous lichen planus
- discuss isotopic labeling
- define terms used in the application
- describe resolution of racemic mixtures
- discuss pharmaceutically acceptable salts and treatment

### Combination Therapies

- list additional therapeutic agents
- describe antibiotics as additional agents
- describe retinoids as additional agents
- describe steroids as additional agents
- describe anti-TNF-alpha agents as additional agents
- describe immunosuppressants as additional agents
- describe JAK inhibitors as additional agents

### Pharmaceutical Formulations and Dosage Forms

- describe pharmaceutical compositions
- formulate for topical administration
- list excipients for topical formulations
- describe surfactants
- formulate for oral administration
- describe sustained release compositions
- formulate with silicified microcrystalline cellulose
- describe unit dosage forms
- determine effective dosage range
- describe liquid forms for administration
- describe kits for treatment of cutaneous lupus erythematosus

### Kits

- describe pharmaceutical kits for treatment of cutaneous lupus erythematosus

## EXAMPLES

- provide examples of JAK kinase assay and JAK1 inhibition in various in vitro and in vivo models

### Example 1. In Vitro JAK Kinase Assay

- describe in vitro JAK kinase assay for testing JAK1 inhibitors

### Example 2. Activated JAK1 is Strongly Expressed in Human CLE Skin Lesions

- investigate JAK1 expression in human CLE skin lesions

### Example 2. JAK/STAT-Associated Innate Inflammatory Pathways are Significantly Activated in Human CLE Skin

- analyze JAK/STAT-associated innate inflammatory pathways in human CLE skin

### Example 3. INCB039110 Significantly Inhibits JAK1-Phosphorylation in Cultured Immortalized Human Keratinocytes

- test JAK1 inhibition by INCB039110 in cultured keratinocytes

### Example 4. Pharmacological JAK1 Inhibition Blocks the Expression of CLE-Typical Proinflammatory Cytokines and Pathway Molecules in Vitro

- investigate pharmacological JAK1 inhibition in vitro

### Example 5. In Vivo Topical Application of INCB039110 Ameliorates CLE-Like Lesions in Lupus-Prone TREX1−/− Mice

- test topical application of INCB039110 in lupus-prone TREX1−/− mice

### Example 6. In Vivo Topical Application of INCB054707 Ameliorates CLE-Like Lesions in Lupus-Prone MRL-Lpr Mice

- test topical application of INCB054707 in lupus-prone MRL-Lpr mice

